How do you decide if a full-time CRO is right for a PE-backed company when sales and marketing are misaligned in 2027?

The two paths: fractional fix vs. full-time CRO

When a PE-backed portfolio company's sales and marketing teams are misaligned, the operating partner and CEO are really choosing between two structurally different interventions, and conflating them wastes both money and runway. The first path is a fractional or interim revenue leader — someone who works 10-20 hours a week (fractional) or takes a full-time 3-6 month seat (interim) with a narrow mandate: audit the CRM, unify lead definitions, install a handoff SLA between marketing and sales, and report findings up to the operating partner. This path assumes the underlying company is otherwise healthy — the compensation plans are reasonable, the VPs are competent, and the gap is coordination, not incentive design. The second path is a full-time CRO who owns the entire revenue organization (sales, marketing, customer success, and RevOps) permanently, reports to the CEO and board, and has hire/fire authority over both VP of Sales and VP of Marketing.

The dividing line between the two paths is authority, not effort. A fractional leader can diagnose that marketing is measured on MQL volume while sales is measured on closed-won revenue, and that no one owns the middle of the funnel — but a fractional leader typically cannot rewrite either VP's compensation plan or terminate one of them, because they lack standing with the board and are not accountable for the P&L they are only advising on. A full-time CRO can do both on day one, because their compensation and their job are already tied to fixing exactly this. The mistake most PE operating partners make is hiring a fractional leader to solve a full-time problem: they get a clean audit and a plan, but the same two VPs who caused the misalignment are still in their seats a quarter later, still measured on the same conflicting numbers, and the diagnosis becomes shelfware. The inverse mistake — hiring a full-time CRO for a tactical gap — is expensive and slow: recruiting alone takes 8-12 weeks, the role costs $250,000-$350,000 in base plus bonus and equity, and installing someone permanent to fix a problem that a 90-day sprint could have solved burns runway the PE firm would rather deploy toward the next acquisition or an add-on deal.

There is a third, hybrid path worth naming even though it isn't a genuine alternative to the first two: promoting an existing VP of Sales or VP of Marketing into an interim head-of-revenue role. This almost never resolves misalignment in a PE-backed company, because the promoted leader carries the bias of their prior function — a promoted VP of Sales will keep blaming marketing for lead quality, and a promoted VP of Marketing will keep blaming sales for poor follow-up — and neither has credibility with the other team. PE operating partners who try this route typically end up hiring a fractional or full-time outsider within two quarters anyway, having lost time and trust in the process.

How to decide between them

The decision comes down to three diagnostic questions the operating partner and CEO should walk through together before making an offer to any candidate, fractional or full-time. First: is there one shared forecast today, or two? If sales reports a pipeline number and marketing reports a separate contribution number and the two have never been reconciled in a single operating review, that is a structural gap — a symptom of no one owning the funnel end to end — and it points toward a full-time CRO, because reconciling two forecasts permanently requires someone with the authority to force one taxonomy across both teams' CRMs and compensation plans. Second: are the VPs' incentives actively working against alignment? If the VP of Sales is paid entirely on self-sourced deals and ignores marketing-generated leads because inbound doesn't count toward quota, no amount of process fixing will change behavior until compensation changes — and changing compensation for direct reports of the CEO usually requires either CEO buy-in strong enough to force it through a fractional advisor's recommendation, or a full-time executive who owns the plan outright. Third: how much runway does the PE firm's hold period give the fix? A typical PE hold is 3-7 years, and if the fund is already 4-5 years into the hold with an exit process starting in 12-18 months, there usually isn't time to run a 90-day fractional diagnosis, wait for board approval on a hire/fire decision, and then bring in a full-time CRO to execute — in that scenario, going full-time immediately is usually the pragmatic choice even if the misalignment looks tactical on the surface, because a clean, provable revenue engine is part of the exit story buyers evaluate.

If the diagnostic points to "fractional," the company should still set a hard checkpoint: at day 60 or day 90, the operating partner reviews whether the misalignment is actually resolved or whether the fractional leader has simply produced a report recommending a full-time hire. That checkpoint is the single most commonly skipped step in PE-backed RevOps fixes — firms hire a fractional leader, get a diagnosis, and then sit on it for two more quarters because no one owns converting the recommendation into an executive search.

What each option actually costs

The economics of the two paths differ by roughly an order of magnitude in year-one cost, and PE operating partners should model both before committing. A fractional revenue leader working 10-20 hours a week typically costs $8,000-$20,000 a month, or roughly $100,000-$240,000 annualized, with no equity component and no long-term severance exposure — the engagement ends when the scope ends, usually 60-90 days for a pure diagnostic-and-fix engagement, sometimes extended to 6 months if implementation work (compensation redesign, CRM rebuild) is layered on. An interim revenue leader taking a full-time seat for 3-6 months runs higher, generally $25,000-$45,000 a month, because they're carrying full operational ownership of the P&L rather than advising, which puts the annualized run-rate in the $300,000-$500,000 range if extended to a year — though interim engagements rarely run that long by design.

A full-time CRO, by contrast, is a permanent balance-sheet commitment: base salary of $250,000-$350,000, a performance bonus tied to EBITDA or revenue growth (often 30-50% of base at target), and an equity or carried-interest component aligned to the eventual exit, plus recruiting fees that typically run 25-33% of first-year total compensation if a search firm is used. All-in, a full-time CRO hire commonly costs $450,000-$700,000 in year one once bonus, equity value, and recruiting fees are counted, and that cost recurs every year the CRO stays, unlike a fractional engagement that terminates on schedule. The PE firm's investment committee will generally require the CRO's cost to be justified against a specific ROI case — often expressed as the CRO needing to compress the sales cycle by 30-40% within 18 months, or reduce cost of customer acquisition by 20-25% within six months, because those are the levers that most directly restore the exit multiple the misalignment was eroding. If a company's total revenue is under roughly $10-15 million, a full-time CRO's all-in cost can represent 4-6% of revenue, which is a hard number for an operating partner to defend unless the misalignment is demonstrably costing more than that in wasted marketing spend and lost deals — a comparison worth running explicitly: quantify the wasted spend (duplicated campaigns, ignored inbound leads, self-sourced sales cycles that took 20-30% longer than pipeline-assisted ones) and set it against the CRO's fully loaded cost before the board approves the role.

There's a middle-cost option worth naming for completeness: converting a fractional engagement into a longer advisory retainer (ongoing at 5-10 hours a week, $4,000-$8,000 a month) after the initial 90-day fix, used to maintain the new taxonomy and compensation structure without paying for a full-time executive. This works when the underlying VPs are competent and just needed the process installed, but it fails the moment either VP leaves or a new one is hired who reverts to old habits, because a part-time retainer holder has no standing to re-enforce the fix against a new hire's resistance.

Implementation: sequencing the first 100 days

Whichever path the PE firm and CEO decide on, the sequencing of the first 100 days determines whether the misalignment actually gets fixed or just gets a new report written about it. For a fractional or interim engagement, the sequence runs in three phases. Days 1-30: audit the CRM, pull every field both teams use to define a lead, an opportunity, and a closed-won deal, and produce a single reconciliation showing exactly where marketing's reported funnel and sales's reported pipeline diverge — this is almost always the fastest way to surface whether the company's problem is tactical or structural. Days 31-60: implement one unified lead-scoring model that both VPs sign off on in writing, enforce it in the CRM with no manual override field, and set a lead-handoff SLA (commonly 24-48 hours from marketing-qualified to sales-accepted) with automatic escalation when it's missed. Days 61-90: deliver a written recommendation to the operating partner — continue with the fix as installed, extend the fractional engagement to cover compensation redesign, or escalate to a full-time CRO search — backed by the reconciled pipeline data from the prior 60 days.

For a full-time CRO, the sequencing is heavier because it includes personnel and compensation authority the fractional path doesn't have. Days 1-30 mirror the audit above but extend into compensation plans for both VPs and their teams. Days 31-60 are when the CRO makes the personnel calls the fractional leader could only recommend — reassigning or replacing a VP who won't commit to a unified process — and begins redesigning compensation so that a meaningful share of each team's variable pay (commonly around 20-30%) is tied to a shared revenue target rather than siloed team metrics. Days 61-90 close with a new reconciled forecast presented to the CEO and the PE firm's operating partner, plus a revised go-to-market budget that typically shifts some portion of marketing spend (often 10-20%) away from top-of-funnel brand activity and toward sales enablement and mid-funnel nurture, since that's usually where PE-backed misalignment does the most damage — marketing generating volume the sales org has no functional way to convert.

Whichever sequence is used, the operating cadence during the first 90 days matters as much as the plan itself: weekly alignment reviews between the revenue leader, the VP of Sales, and the VP of Marketing, with the CEO present, keep the fix from quietly reverting once attention moves elsewhere — the most common failure mode in PE-backed companies isn't picking the wrong path, it's picking the right path and then not holding the cadence long enough for the new taxonomy and incentives to actually stick.

Related questions

How much does a fractional CRO cost compared to a full-time CRO?

Fractional engagements run roughly $8,000-$20,000 a month with no equity; full-time CROs cost $450,000-$700,000 in year one once bonus, equity, and recruiting fees are included, and that cost recurs annually.

Who should a CRO report to in a PE-backed company?

Directly to the CEO, with regular reporting to the PE firm's operating partner — reporting through a CFO who controls the budget undermines the CRO's authority to redesign compensation and enforce process changes.

Can a fractional revenue leader fire an underperforming VP?

Generally no — fractional leaders advise and diagnose but rarely hold the standing or P&L accountability needed to make personnel decisions; that authority typically requires a full-time executive role.

What's the fastest way to tell if misalignment is tactical or structural?

Check whether sales and marketing produce one reconciled forecast or two separate numbers that have never been compared line by line — two forecasts that never converge is the clearest sign of a structural gap.

How long should a PE firm give a fix before escalating to a full-time hire?

90 days is the standard checkpoint — if a fractional or interim leader hasn't produced a single reconciled forecast and a working lead-handoff SLA by then, escalate to a full-time CRO search.

FAQ

What is the single biggest mistake PE firms make when deciding between fractional and full-time revenue leadership? Hiring based on urgency rather than root cause — panicking over a bad quarter and jumping straight to a full-time CRO search when the actual problem is a 90-day fixable process gap, or the reverse, hiring a fractional advisor to paper over a compensation and personnel problem that only a full-time executive has the authority to fix.

Does a PE-backed company need a RevOps function separate from the CRO? Yes, ideally — RevOps is the operational layer (CRM administration, pipeline reporting, process enforcement) that should report to whoever holds revenue accountability, whether that's a fractional leader, an interim CRO, or a full-time one. Without a dedicated RevOps owner, even a good CRO spends their own time on CRM hygiene instead of strategy.

How do you know if the misalignment is actually a product-market fit problem instead of a sales-marketing coordination problem? If a unified lead-scoring model, a clean SLA, and aligned compensation are all in place for two full quarters and the pipeline conversion rate still doesn't improve, the company should look at whether the product is solving a problem the target buyer actually has — no revenue leader, fractional or full-time, can align a sales and marketing motion around a product that doesn't convert regardless of process.

What happens if the PE firm's hold period is too short to justify a full-time CRO? If the fund is inside 18-24 months of a planned exit, a full-time CRO's ramp time and compensation cost often don't pay back before the sale, so an interim or fractional leader who can show quick, provable pipeline reconciliation is usually the more defensible choice for the exit story.

Should the same person who diagnoses the misalignment also be the one who fixes it? Not necessarily — a fractional leader's diagnostic work is valuable even if the company ultimately hires a different, full-time CRO to execute the fix; the diagnosis and the reconciled data become the new hire's onboarding audit, which shortens their own first-30-days ramp considerably.

Is it normal for a PE-backed company to go through more than one revenue leader before the misalignment is fully resolved? Yes — many portfolio companies use a fractional leader for diagnosis, then an interim leader for execution, then convert to full-time once the operating cadence has proven durable for two or more quarters; treating this as a sequence rather than a single hiring decision reduces the risk of committing to the wrong structure too early.

Sources

• https://www.bain.com
• https://hbr.org
• https://www.mckinsey.com
• https://www.gartner.com
• https://www.forbes.com
• https://www.bridgegroupinc.com
• https://openviewpartners.com
• https://www.pehub.com

Related on PULSE

• How fractional CRO engagements typically structure pricing and scope
• What a 100-day plan looks like for a newly acquired PE portfolio company
• How to design compensation plans that align sales and marketing incentives
• When to bring in interim leadership versus a permanent executive hire
• How RevOps functions should be structured to report into revenue leadership